Skip to main content
Premium Trial:

Request an Annual Quote

Disappointing End

An Alzheimer's disease drug trial has had disappointing results, the New York Times reports.

The trial focused on an extended family in Colombia, as many members of that family have a genetic alteration that leads them to develop Alzheimer's disease in their mid-40s to mid-50s. According to the Times, 169 individuals harboring that mutation received either Genentech's crenezumab or placebo and an additional 83 individuals without the mutation received placebo as a means of obscuring the identities of individuals with the mutation.

However, Roche announced this week that this trial of crenezumab, an anti-amyloid monoclonal antibody drug, did not show that the drug had a statistically significant clinical benefit affecting either the rate of change in cognitive abilities or episodic memory function.

"We're disappointed that crenezumab did not show a significant clinical benefit," Eric Reiman from the Banner Alzheimer's Institute and team leader of the trial, said during a press briefing, according to the Times. "Our hearts go out to the families in Colombia and to everyone else who would benefit from an effective Alzheimer's prevention therapy as soon as possible. At the same time, we take heart in the knowledge that this study launched and continues to help shape a new era in Alzheimer's prevention research."

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.